Unusual redo mitral valve replacement for bleeding in Glanzmann thrombasthenia

Asian Cardiovascular and Thoracic Annals

Volumn 24, Issue 1, 2016, Pages 57-59

  Garcia Villarreal, Ovidio A ^a   Fernández Ceseña, Ernesto ^a   Solano Ricardi, Mercedes ^a   Aguilar García, Alma L ^a   Vega Hernández, Raquel ^a   Angel Soto, Gustavo Del ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

autosomal dominant; Bioprosthesis; Glanzmann thrombasthenia; Heart valve prothesis implantation; Mitral valve; Thrombasthenia; Warfarin

Indexed keywords

RECOMBINANT ACTIVATED FACTOR VII; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTICOAGULATION; ARTICLE; BACTERIAL ENDOCARDITIS; BLEEDING; BLEEDING TIME; CARDIOPULMONARY BYPASS; CASE REPORT; DRUG DOSE REDUCTION; EPISTAXIS; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; GLANZMANN DISEASE; HEMATOTHORAX; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICAL HISTORY; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; PERICARDIAL EFFUSION; PETECHIA; SCREENING TEST; SINGLE DRUG DOSE; STREPTOCOCCUS INFECTION; THROMBOCYTE AGGREGATION; YOUNG ADULT; BIOPROSTHESIS; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; COMPLICATION; DEVICE REMOVAL; DEVICES; GENETICS; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE HEMORRHAGE; PROSTHESIS DESIGN; REOPERATION; RISK FACTOR; THROMBASTHENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BIOPROSTHESIS; BLOOD COAGULATION; DEVICE REMOVAL; GASTROINTESTINAL HEMORRHAGE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMATURIA; HUMANS; MALE; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; PERICARDIAL EFFUSION; POSTOPERATIVE HEMORRHAGE; PROSTHESIS DESIGN; REOPERATION; RISK FACTORS; THROMBASTHENIA; TREATMENT OUTCOME; WARFARIN; YOUNG ADULT;

EID: 84949843797     PISSN: 02184923     EISSN: 18165370     Source Type: Journal    
DOI: 10.1177/0218492314539333     Document Type: Article

References (8)

1. Glanzmann E. "Hereditäre hämorrhagische Thrombasthenie. Ein Beitrag zur Pathologie der Blutplättchen. J Kinderkrankenschwester 1918;88:11. Available at: http://books.google.co.uk/books?id = YnKqHHJ4BoEC&pg = PA73&lpg = PA73&dq = %22Heredit%C3%A4re + h%C3%A4morrh%C3%A4gische+Thrombasthenie.&source=bl&ots=xe5kYcD77e&sig=FNzxBxfY19IIyz5DevyLZ-fJVZI&hl=en&sa=X&ei=qy92U7j1Ms7jO9P5gVA&ved=0CDMQ6AEwAQ#v=onepage&q=%22Heredit%C3%A4re%20h%C3%A4morrh%C3%A4gische%20Thrombasthenie.&f=false. Accessed May 16, 2014.
2. Gruel Y, Pacouret G, Bellucci S, Caen J,. Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant successfully treated with a low molecular weight heparin. Blood 1997; 90: 888-890.
3. Rezende SM,. Secondary prophylaxis with warfarin for recurrent thrombosis in a patient with Glanzmann thrombasthenia and F5 G1691A. Br J Haematol 2011; 156: 144-144.
4. Alamelu J, Liesner R,. Modern management of severe platelet function disorders. Br J Haematol 2010; 149: 813-823.
5. Seligsohn U,. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents [Review]. Pathophysiol Haemost Thromb 2002; 32: 216-217.
6. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
7. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
8. López-Farré A, Macaya C. Platelets: the physiology of activation and inhibition. Rev Esp Cardiol 2013;13(Suppl B):2-7. Available at: http://pdf.revespcardiol.org/watermark/ctl-servlet?-f=10&pident-articulo=90200688&pident-usuario=0&pcontactid=&pident-revista=25&ty=69&accion=L&origen=cardio&web=www.revespcardiol.org&lan=es&fichero=25v13nSupl.2a90200688pdf001.pdf. Accessed May 16, 2014.